Last reviewed · How we verify
NCT05217888: Sentinel
The Sentinel Registry
trial testing Sentinel in Aortic Valve Disease in 158 participants. Completed in 20 May 2025.
20 May 2025
Quick facts
| Lead sponsor | Duk-Woo Park, MD |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 158 |
| Start date | 18 May 2022 |
| Primary completion | 20 May 2025 |
| Estimated completion | 20 May 2025 |
| Sites | 10 locations across South Korea |
Drugs / interventions tested
- Sentinel
Conditions studied
- Aortic Valve Disease — all drugs for Aortic Valve Disease →
- Transcatheter Aortic Valve Implantation — all drugs for Transcatheter Aortic Valve Implantation →
- Transcatheter Aortic Valve Replacement — all drugs for Transcatheter Aortic Valve Replacement →
Sponsor
Duk-Woo Park, MD — full company profile →
Who can join
19 and older, any sex, with Aortic Valve Disease or Transcatheter Aortic Valve Implantation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This registry is to evaluate procedural outcomes and safety outcomes of cerebral protection devices during transfemoral TAVR in real-world clinical practice. The data from this registry will be compared with the extracted data from the TP TAVR registry(NCT038262664) using Propensity Score Matching.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effect of cerebral embolic protection device on new cerebral embolism during transcatheter aortic valve replacement: A prospective sentinel registry.
Park HS, Suh CH, Ahn JM, Kang DY, et al · · 2026 · cited 1× · PMID 40816554 · DOI 10.1016/j.ahj.2025.08.006
Verify or expand the search:
- PubMed search for NCT05217888
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Aortic Valve Disease
Currently open trials in the same condition.
- NCT07008911 — CardioHeartConnect: Commercially Available Fitness for Cardiac Rehabilitation · NA · recruiting
- NCT07267117 — Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease · recruiting
- NCT07021612 — A Clinical and Imaging Registry of Transcatheter Aortic Valve Implantation Using JenaValve System/ J-Valve System for Pa · recruiting
- NCT06896227 — TAVR: The Impact of Prothesis Positioning on Valvular and Coronary Hemodynamics · NA · recruiting
- NCT06189976 — Rapid Atrial Pacing After TAVI to Predict Pacemaker Implantation · NA · recruiting
Other Duk-Woo Park, MD trials
Trials by the same sponsor.
- NCT04416581 — Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gast · Phase 4 · recruiting
- NCT04351984 — Transcatheter Mitral Valvuloplasty Pilot Study · completed
- NCT04443530 — Evaluation of Effectiveness and Safety of Ultimaster™ Tansei™ Stent in Routine Clinical Practice · recruiting
- NCT03826264 — Transpacific TAVR Registry · recruiting
- NCT03465644 — TAILored Versus COnventional AntithRombotic StratEgy IntenDed for Complex HIgh-Risk PCI · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05217888 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Duk-Woo Park, MD
- Last refreshed: 13 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05217888.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing